Australian biotech firm Imugene partners with Kincell Bio for $6M to sell its cell therapy manufacturing facility, focusing on immuno-oncology therapies.
Imugene, an Australian biotech firm, partners with Kincell Bio for $6M to sell its cell therapy manufacturing facility. Imugene will focus on immuno-oncology therapies, while Kincell Bio utilizes the facility for continued growth and innovation. This strategic partnership aims to leverage Kincell Bio's expertise in cell therapy manufacturing for both companies' benefit.
April 16, 2024
3 Articles